ADVICE, NCT02394730: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints |
|
|
| Completed | 1/2 | 65 | US, RoW | vorapaxar, Zontivity, Placebo, sugar pill | Kirby Institute, National Institute of Allergy and Infectious Diseases (NIAID), University of Minnesota, University of Melbourne, Merck Sharp & Dohme LLC | HIV | 11/17 | 01/18 | | |
